

# the **ADBL** report

Issue #111, November 2019

An Official Accompaniment to the Alberta Drug Benefit List (ADBL) produced by Alberta Blue Cross The Expert Committee on Drug Evaluation and Therapeutics (ECDET)

#### EXPERT COMMITTEE MEMBERS:

Scott Klarenbach, MD, MSc (Health Econ), FRCPC, (Chair)  
Fiona Clement, PhD, (Vice-Chair)  
Caitlin A. Clarke, BScPharm, PharmD  
Margaret Gray, BSP, FCSHP  
Mike Kolber, BSc, MD, CCFP, MSc  
Naeem Ladhani, BScPharm  
Tony Nickonchuk, BScPharm  
Glen J. Pearson, BScPharm, PharmD, FCSHP, FCCS  
Jeremy Slobodan, BSP  
Donna Woloschuk, BSP, PharmD, M.Ed. FCSHP

#### ALBERTA HEALTH LIAISON:

Chad Mitchell, BSc Pharm, MSc

#### ADMINISTRATIVE AND SCIENTIFIC SUPPORT:

Julia Chan, BSc (Pharm)  
Amanda Chung, BSc (Pharm)  
Sherry Dieleman, BSc (Pharm), MSc  
Connie Lussier, BSP, MA

## In this issue:

- *Brief Summary of Drug Review Activities*
- *Highlights of:*
  - ❖ *Products Originally Reviewed via the CDR*
  - ❖ *Interchangeable Drug Products Added*
- *Addition of Single Source Drug Products*

## *Brief Summary of Drug Review Activities*

The Expert Committee on Drug Evaluation and Therapeutics met on September 24, 2019. The Committee reviewed Manufacturer submissions for thirteen (13) Drug Products for potential listing, or change in listing, on the ADBL. The Committee also considered information for a number of supplementary assessments of the coverage status of two (2) Drug Products.

In addition to Drug Products reviewed by the Expert Committee, seven (7) Drug Products underwent Expedited Review for listing on the ADBL effective October 1, 2019, and seven (7) Drug Products underwent Expedited Review for listing on the ADBL effective November 1, 2019.

The following are highlights of recent changes to the ADBL and other topics of general interest. A complete list of changes, as well as the full ADBL may be accessed at <https://www.ab.bluecross.ca/dbl/publications.php>

## *Highlights of Products Originally Reviewed via the Common Drug Review (CDR)*

The following Drug Product was reviewed by CDR and the Expert Committee and added to the ADBL effective October 1, 2019:

- **GALAFOLD\* 123 mg oral capsule** (migalastat) (AMI) via Special Authorization (SA)

A complete list of changes, as well as the full ADBL may be accessed at <https://www.ab.bluecross.ca/dbl/publications.php>.

\*Please refer to the current ADBL for explanations of coverage, including a listing of coverage criteria (where applicable).\*

## ***Highlights of Interchangeable (IC) Drug Products Added***

Addition of the following Entry IC Drug Products to the *ADBL* has resulted in the creation of New IC Groupings, effective October 1, 2019:

- **VORICONAZOLE\* 200 mg/vial injection** (voriconazole) (JPC) via Restricted Benefit/SA

Addition of the following Entry IC Drug Products to the *ADBL* has resulted in the creation of New IC Groupings, effective November 1, 2019:

- **ATROPINE 1% ophthalmic solution** (atropine sulfate) (PSL)
- **JAMP ITRACONAZOLE\* 10 mg/mL oral solution** (itraconazole) (JPC) via Restricted Benefit/SA
- **METHADONE HYDROCHLORIDE 10 mg/mL oral solution** (methadone hydrochloride) (SDZ)

## ***Addition of Single Source Drug Products***

The following Drug Products were reviewed by the Expert Committee and added to the *ADBL* effective November 1, 2019

- **RAN-CEFPROZIL 25 mg/mL & 50 mg/mL oral suspensions** (cefprozil) (RAN)

A complete list of changes, as well as the full *ADBL* may be accessed at <https://www.ab.bluecross.ca/dbl/publications.html>.

\*Please refer to the current *ADBL* for explanations of coverage, including a listing of coverage criteria (where applicable).\*